IRAKIMID Trademark

Trademark Overview


On Thursday, June 15, 2023, a trademark application was filed for IRAKIMID with the United States Patent and Trademark Office. The USPTO has given the IRAKIMID trademark a serial number of 98044278. The federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE FILED as of Monday, October 21, 2024. This trademark is owned by Kymera Therapeutics, Inc.. The IRAKIMID trademark is filed in the Pharmaceutical Products and Computer & Software Services & Scientific Services categories with the following description:

Pharmaceutical and medical preparations for the treatment of cancer, immune inflammatory diseases, and autoimmune diseases; pharmaceutical therapeutics for the treatment of cancer, immune inflammatory diseases, and autoimmune diseases; protein degraders being pharmaceutical preparations for the treatment of cancer, immune inflammatory diseases, and autoimmune diseases

Research and development of therapeutic drugs for the treatment of cancer, immune inflammatory diseases, and autoimmune diseases; research and development of therapeutic antibodies and pharmaceuticals; research and development of technology in the field of therapeutic antibodies, pharmaceuticals and biopharmaceuticals; development of pharmaceutical preparations and medicines; pharmaceutical drug development services and drug discovery services; medical research for development of therapeutic modalities for treatment of diseases
irakimid

General Information


Serial Number98044278
Word MarkIRAKIMID
Filing DateThursday, June 15, 2023
Status606 - ABANDONED - NO STATEMENT OF USE FILED
Status DateMonday, October 21, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, January 23, 2024

Trademark Statements


Goods and ServicesPharmaceutical and medical preparations for the treatment of cancer, immune inflammatory diseases, and autoimmune diseases; pharmaceutical therapeutics for the treatment of cancer, immune inflammatory diseases, and autoimmune diseases; protein degraders being pharmaceutical preparations for the treatment of cancer, immune inflammatory diseases, and autoimmune diseases
Goods and ServicesResearch and development of therapeutic drugs for the treatment of cancer, immune inflammatory diseases, and autoimmune diseases; research and development of therapeutic antibodies and pharmaceuticals; research and development of technology in the field of therapeutic antibodies, pharmaceuticals and biopharmaceuticals; development of pharmaceutical preparations and medicines; pharmaceutical drug development services and drug discovery services; medical research for development of therapeutic modalities for treatment of diseases

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateWednesday, July 19, 2023
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateWednesday, July 19, 2023
Primary Code042
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameKymera Therapeutics, Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressWatertown, MA 02472

Party NameKymera Therapeutics, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressWatertown, MA 02472

Trademark Events


Event DateEvent Description
Monday, June 19, 2023NEW APPLICATION ENTERED
Wednesday, July 19, 2023NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Friday, December 8, 2023ASSIGNED TO EXAMINER
Thursday, December 14, 2023EXAMINERS AMENDMENT -WRITTEN
Thursday, December 14, 2023EXAMINERS AMENDMENT E-MAILED
Thursday, December 14, 2023NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Thursday, December 14, 2023EXAMINER'S AMENDMENT ENTERED
Thursday, December 14, 2023APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, January 3, 2024NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, January 23, 2024PUBLISHED FOR OPPOSITION
Tuesday, January 23, 2024OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, March 19, 2024NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Wednesday, June 26, 2024APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Wednesday, June 26, 2024ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Wednesday, June 26, 2024TEAS CHANGE OF OWNER ADDRESS RECEIVED
Wednesday, June 26, 2024TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Wednesday, June 26, 2024TEAS CHANGE OF CORRESPONDENCE RECEIVED
Wednesday, June 26, 2024TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
Monday, October 21, 2024ABANDONMENT - NO USE STATEMENT FILED
Monday, October 21, 2024ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED